Navigation Links
Teva's Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinson's Disease
Date:3/4/2009

mong PCPs.

"Our survey results indicate that PCPs need to be educated on the advantages of prescribing a non-ergotic dopamine agonist in the place of levodopa/carbidopa first line," added Dr. Borde. "Surveyed neurologists, on the other hand, have become very comfortable prescribing a non-ergotic dopamine agonist ahead of levodopa/carbidopa and some no longer even use the drug first line."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS Lifelink: Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more in
'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
2. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
3. Demand for VScan Dengue Fever Test Kits Increases
4. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
5. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
6. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
7. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
8. New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion
9. Orqis(R) Medicals Cancion(R) System Significantly Increases Cardiac Performance
10. Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases
11. New Pharma Business Model Increases Pressure on Staff Communicating Trial Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud Analytics, ... analytics technology, announces it is working with Intel ... for the new Lockheed Martin Healthcare Technology Alliance. ... health information technology providers, medical technology companies and ... and innovation to improve care in rapidly evolving ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Institute (C-Path), and TransCelerate BioPharma, Inc. are pleased to announce that data standards ... been published for use on the CDISC website . These three Therapeutic ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water needed, the refreshing ... as a simple way to get the natural ingredients that may help with ...
(Date:7/30/2015)... ... July 30, 2015 , ... Google recently announced that it will be disclosing ... discussed in a June 8, 2015 article published by Nasdaq , the powerful ... caused by its computer-driven cars, which such industry players as Tesla CEO Elon Musk ...
(Date:7/30/2015)... CA (PRWEB) , ... July ... ... recently released a video, “Beachside Nursing Center,” to announce its position as ... five-star ratings. Beachside's administrator and staff members support the CMS rating system, ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zejax is a New Way ... Training Capability , World renown body weight trainer, Paul Ziachik, announces today ... dramatically increases a person’s training capability. , The American College of Sports Medicine ...
Breaking Medicine News(10 mins):Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Beachside Nursing Center Releases New Video 2Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2
... , CHICAGO, Nov. 24 The holiday season can be ... But for many people, especially those recovering from an eating ... failures and anxiety about an uncertain future. Family gatherings with ... be challenging and sometimes awkward. , "In my ...
... , , FLINT, Mich., Nov. 24 ... insurance plans designed specifically for individuals 18 to 64 ... coverage directly. , The new HealthPlus Signature ... agents and brokers throughout the HealthPlus service area. More information, ...
... ... but research will be presented at the upcoming 2009 Advances in Inflammatory Bowel Diseases, ... that may identify a causative mutation for Crohn’s disease. , ... New York, NY (Vocus) November 24, 2009 ...
... , PITTSBURGH, Nov. 24 While the ... this time of the year can be difficult for those ... every day is difficult for children and families. The holiday ... , The Highmark Caring Place, A Center for Grieving Children, ...
... Ala., Nov. 24 HealthSouth Corporation (NYSE: HLS ) ... Lynch 2009 Credit Conference in New York on Dec. 2-3, 2009. ... be speaking on Thursday, Dec. 3, 2009, at 3:40 p.m. ET. ... http://investor.healthsouth.com by clicking on an available link. , ...
... rates didn,t differ greatly between high- and low-volume centers, ... Do hospitals that conduct the most angioplasties necessarily produce ... research had suggested that "practice makes perfect" when it ... over 30,000 patients finds low- and high-volume hospitals performing ...
Cached Medicine News:Health News:When Holiday Meals Aren't a Gift 2Health News:When Holiday Meals Aren't a Gift 3Health News:HealthPlus Offers New Insurance Plans for Consumers Seeking Health Coverage on Their Own 2Health News:HealthPlus Offers New Insurance Plans for Consumers Seeking Health Coverage on Their Own 3Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 3Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 4Health News:Highmark Caring Place Resources Help Children and Families Who Are Grieving During the Holidays 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 3
Extended angled sharp electrode - 1/box....
... 200, the state of the art in ... Zeiss optics with,the wide range of ICS ... as well as with an unusual scope ... stability and unique ergonomically designed. And Axiovert ...
... the way it implements the confocal principle, ... system is unmatched. It allows multi fluorescence ... and efficiency. Unprecedented flexibility for individual applications. ... guarantee fast and efficient structural and functional ...
... are the hallmark of these stereozoom fluorescent ... The top (incident) circular 9W fluorescent ring ... remaining cool to the touch. Binocular and ... to 44x zoom magnification or high-power 20x ...
Medicine Products: